NCT04799847 2023-02-13
Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine
LintonPharm Co.,Ltd.
Phase 1/2 Unknown
Clinical Trials
13 trialsNCT04222114 2023-01-31
Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis
LintonPharm Co.,Ltd.
Phase 3 Unknown
NCT04819399 2022-04-05
Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC
Lindis Biotech GmbH
Phase 1 Unknown
NCT00326885 2018-10-17
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
Neovii Biotech
Phase 2 Completed
NCT01504256 2018-01-23
CatuNeo
AIO-Studien-gGmbH
Phase 2 Completed
NCT01246440 2016-08-11
Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission
Grupo Español de Investigación en Cáncer de Ovario
Phase 2 Completed
NCT01815528 2015-02-18
Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer
Charite University, Berlin, Germany
Phase 2 Completed
NCT00464893 2013-12-04
Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection
Neovii Biotech
Phase 2 Completed
NCT01320020 2013-07-02
A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients
Neovii Biotech
Phase 1 Terminated
NCT00563836 2012-10-03
Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer
Neovii Biotech
Phase 2 Completed
NCT00377429 2012-07-19
Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy
Neovii Biotech
Phase 2 Completed
NCT00352833 2007-10-26
Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma
Neovii Biotech
Phase 2 Completed
NCT00189345 2006-11-08
Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients
AGO Study Group
Phase 2 Completed